Alnylam Pharmaceuticals Underperformed Amid Clinical Trial Concerns
In its second-quarter 2026 investor letter, American Century Investments Focused Dynamic Growth Fund highlighted that Alnylam Pharmaceuticals (NASDAQ:ALNY) detracted from the fund's performance due to underperformance in biotechnology stocks. The company’s stock returned 13.6% over the past month but fell by nearly 45% year-to-date as of September 9, 2026. Concerns around upcoming late-stage clinical trial results contributed to its poor market performance despite strong recent financial metrics. The broader U.S. equity markets saw robust gains in Q2 driven by solid earnings and AI stock momentum, though healthcare stocks like Alnylam lagged behind other sectors such as industrials and aerospace. The fund returned 16.38%, slightly below the Russell 1000 Growth Index's performance. Alnylam Pharmaceuticals has a market capitalization of $34.52 billion with its stock trading between $197.81 to $495.55 over the past year.
Tickers: $ALNY
Topics: biopharmaceuticals mutual fund holdings stock underperformance